CRANBURY, N.J.--(BUSINESS WIRE)--Rare Disease Report®, the digital component of Rare Disease Communications®, recently shared an article written by the renowned physician and medical epidemiologist Paul Mehta, M.D., which focuses on new research opportunities for clinicians involved with amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease.
“As we increase in the population affected by ALS, the chances for a clinician to see a patient with this disease also increases simultaneously. Through our partnerships like the most recent one with the National ALS Registry, we aim to provide the most relevant information to clinicians, researchers and advocates, which in return would benefit the patients,” said James Radke, Ph.D., vice president, editorial, Rare Disease Communications®.
Per Dr. Mehta’s findings, ALS affects more than 16,000 people in the United States and results in death within three to five years of symptom onset. Additionally, an estimated of 5 to 10 percent of the cases are due to heredity, and the remaining 90 to 95 percent are due to unknown etiology, according to Dr. Mehta, of the Agency for Toxic Substances and Disease (ASTDR) at the Centers for Disease Control and Prevention in Atlanta. However, external factors such as smoking, alcohol consumption, pesticides, and head trauma can also contribute to the development of ALS.
While discussing the new treatments and research options, Dr. Mehta said, “just recently, a new clinical treatment for ALS was FDA approved—marking only the second treatment option available in over two decades. In addition, the recent success of the ‘ice bucket challenge’ [an online social media fundraiser] has helped propel awareness of ALS forward.”
To continue to advance the research for ALS, Dr. Mehta highly recommends patients, researchers, and clinicians visit the Agency for Toxic Substances and Disease Registry National ALS Biorepository, which advances ALS research by collecting biological samples from people with ALS and epidemiologic data.
To read to the full article, visit http://www.raredr.com/news/als-update-clinicians.
About Rare Disease Communications®
Rare Disease Communications® is a healthcare communications and media company focused on the rare disease community and dedicated to raising awareness of rare diseases and orphan drugs so that patients will be diagnosed and treated more efficiently. Rare Disease Communications® is part of the Michael J. Hennessy Associates (MJH) Inc. family of businesses, based in Cranbury, New Jersey. MJH Associates is dedicated to improving quality of life through healthcare education, research and communication. To learn more, visit mjhassoc.com.